Verapamil Hydrochloride Tablets

1. Verapamil hydrochloride is a calcium ion antagonist. It exerts its pharmacological effects by regulating the influx of calcium ions on the cell membranes of myocardial conduction cells, myocardial contractile cells, and arterial smooth muscle cells, but does not change the serum calcium concentration. 2. Verapamil hydrochloride dilates the main coronary arteries and arterioles in normal and ischemic parts of the heart, antagonizes spontaneous or ergonovine-induced coronary artery spasm, increases the delivery of myocardial oxygen to the heart of patients with coronary artery spasm, relieves and prevents coronary artery spasm; verapamil reduces total peripheral resistance and reduces myocardial oxygen consumption. It can be used to treat variant angina and unstable angina. 3. Verapamil reduces the influx of calcium ions, prolongs the effective refractory period of the atrioventricular node, slows conduction, and can reduce

The main ingredient and chemical name of this product are: α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-isopropylphenylacetonitrile hydrochloride

This product is a sugar-coated tablet, which appears white after removing the sugar.

1 Angina pectoris: variant angina pectoris; unstable angina pectoris; chronic stable angina pectoris. 2 Arrhythmia: combined with digoxin to control the ventricular rate in chronic atrial fibrillation and/or atrial flutter; prevent recurrent paroxysmal supraventricular tachycardia. 3 Essential hypertension.

Individualized treatment is achieved by adjusting the dose. The safe and effective dose is not more than 480 mg/day. 1 Angina pectoris: The general dose is 80-120 mg/time of oral verapamil three times a day. The safe dose for patients with liver dysfunction and the elderly is 40 mg/time, orally three times a day. About 8 hours after taking the drug, decide whether to increase the dose based on the efficacy and safety assessment. 2 Arrhythmias: For patients with chronic atrial fibrillation who are treated with digitalis, the total daily dose is 240-320 mg, taken orally three or four times a day. For the prevention of paroxysmal supraventricular tachycardia (patients not taking digitalis), the total daily dose for adults is 240-480 mg, taken orally three or four times a day. Age 1-5 years old: daily dose 4-8 mg

Take the recommended single dose and total daily dose as the starting dose and gradually adjust the dose upward. Serious adverse reactions are rare. Adverse reactions with an incidence of 1-10%: constipation (7.3%); dizziness, mild headache (3.5%); nausea (2.7%); hypotension (2.5%); headache (2.2%). Peripheral edema (2.1%); congestive heart failure (1.8%); sinus bradycardia, I, II or III degree atrioventricular block; rash (1.2%); fatigue; palpitations; increased transaminases, with or without increased alkaline phosphatase and bilirubin, which are sometimes transient and may disappear even with continued use of verapamil. Adverse reactions with an incidence of <1%: hypotension; tachycardia; flushing; galactorrhea; gingival hyperplasia; non-obstructive paralytic intestinal infarction

1 Severe left ventricular dysfunction. 2 Hypotension (systolic blood pressure less than 90 mmHg) or cardiogenic shock. 3 Sick sinus syndrome (except patients with a pacemaker installed and functioning). 4 II or III degree atrioventricular block (except patients with a pacemaker installed and functioning). 5 Patients with atrial flutter or atrial fibrillation combined with atrioventricular bypass pathway. 6 Patients known to be allergic to verapamil hydrochloride.

Precautions for children: Safety and efficacy in children under 18 years of age have not been established. Precautions for pregnancy and lactation: Verapamil should not be used in the first 6 months of pregnancy because there is no experience with its use in pregnant women. Verapamil should not be taken in the last 3 months of pregnancy unless the benefits outweigh the risks. Precautions for the elderly: The elimination half-life may be prolonged in elderly patients, and it must be considered that hepatic or renal insufficiency is more common in the elderly. Generally, a lower starting dose is used in the elderly.

1 Cytotoxic drugs such as cyclophosphamide, vincristine, procarbazine, prednisone, vinblastine, doxorubicin, and cisplatin reduce the absorption of verapamil. 2 Phenobarbital, hydantoin, vitamin D, sulfamethoxazole, and ramifluan reduce the plasma concentration of verapamil by increasing liver metabolism. 3 Cimetidine may increase the bioavailability of verapamil. 4 Verapamil inhibits the elimination of ethanol, leading to increased ethanol concentration in the blood, which may prolong the toxic effects of alcohol. 5 A few cases reported that the combined use of verapamil and aspirin prolonged bleeding time compared with aspirin alone. 6 Combined with beta-blockers

Keep sealed.

40mg

24 months

Henan Jiushi Pharmaceutical Co., Ltd.

• Founded in:

  2002-06-24

• Address:

  Southeast of Zhoubu Village, Huixian City

• Tax NO.:

  91410700173249269M

• Registered Funds:

  48 million yuan

• Website:

  Log in to view

• Email:

  Log in to view